Navigation Links
Improving care and knowledge in translational research to fight breast cancer
Date:4/15/2008

Berlin, 15 April 2008 -- European breast cancer specialists have taken a significant step forward in the fight against breast cancer by bringing together world leaders in breast cancer research and treatment at an innovative European scientific meeting, IMPAKT (IMProving cAre and Knowledge in Translational research).

The first IMPAKT meeting, to be held 7-9 May 2009 in Brussels, Belgium, is designed to present and discuss advances in translational research and ways to quickly transform laboratory discoveries into tools that clinicians can use to help make decisions about the way they treat patients in their daily practice.

With breast cancer being the most prevalent cancer in women worldwide, collaboration to fight this devastating disease is necessary. IMPAKT fills an urgent need within the oncology community to coordinate efforts to bring the fruits of advances in science and technology to the patients bedside, says Dr. Martine Piccart, Co-Chair of the meeting.

Building on existing high-level international research collaborations developed by the Breast International Group (BIG) and combining this with the other partners reputations for organizing high quality scientific and educational meetings, IMPAKT will offer a platform for discussing the latest developments in translational research, biomedical technologies and novel therapeutics in breast cancer, adds Dr. Jos Baselga, conference Co-Chair with Dr. Piccart.

IMPAKT is being launched by BIG and the European Society for Medical Oncology, in collaboration with the St. Gallen Primary Therapy of Early Breast Cancer Conference; the three European Breast Cancer Conference partners, which are The European Organisation for Research and Treatment of Cancer Breast Cancer Group, The European Society of Breast Cancer Specialists, and Europa Donna The European Breast Cancer Coalition; and with the support of the European School of Oncology.

We have succeeded in creating a model of direct collaboration between professional medical societies, research groups and cancer patient organizations. This underlines the IMPAKT organizers commitment to stimulate much needed communication across basic, translational and clinical research in breast cancer, said Dr. Baselga.

The meeting will encourage researchers and clinicians to share best practices and provide participants with information on the skills and techniques needed today to apply cutting-edge research to the clinical setting.

While IMPAKT is primarily a scientific meeting, it also includes a full-day training course for young oncologists to help them better understand the new translational research technologies. They will also gain insights into future opportunities in research, and have the possibility to link up with the international network of breast cancer experts.


'/>"/>

Contact: Gracemarie Bricalli
communication@esmo.org
41-079-778-5177
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. Improving detection of nuclear smuggling goal of computer model of mechanical engineer
2. UV light improving chances of fighting cancer
3. Improving science, technology in Africa is aim as G-8, African, UN experts convene in Berlin
4. A tall story: New research adds to growing body of knowledge of genetics of height
5. A call to infuse scientific knowledge into the human experience
6. Rutgers scientists research reveals critical knowledge about the nervous system
7. UD hosts conference on knowledge-based partnerships Nov. 2
8. Fossil data plugs gaps in current knowledge, study shows
9. Translational research patented first experimental treatment against idiopathic pulmonary fibrosis
10. AACR, BCRF award inaugural grants in translational breast cancer research
11. NIH awards nearly $23M to University of Chicago for translational research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/21/2016)... 2016 NuData Security announced today that Randy ... principal product architect and that Jon Cunningham ... development. Both will report directly to Christopher ... reflect NuData,s strategic growth in its product and ... demand and customer focus values. ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/9/2016)... leader in attendance control systems is proud to announce the introduction of fingerprint attendance ... the right employees are actually signing in, and to even control the opening of ... ... ... Photo - ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with ... in this eBook by providing practical tips, tools, and strategies for clinical researchers. ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: